Drug Profile
VT 1021
Alternative Names: VT-1021Latest Information Update: 01 Jun 2023
Price :
$50
*
At a glance
- Originator Vigeo Therapeutics
- Developer Global Coalition for Adaptive Research; Vigeo Therapeutics
- Class Antineoplastics; Peptides
- Mechanism of Action Thrombospondin 1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Glioblastoma
- Phase I/II Solid tumours
Most Recent Events
- 02 Jun 2023 Updated efficacy and pharmacodynamics data from a phase I/II trial in Solid tumors presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 06 Jul 2022 Phase-II/III clinical trials in Glioblastoma (First-line therapy, Late-stage disease, Newly diagnosed) in USA (IV) (NCT03970447)
- 06 Jul 2022 Phase-II/III clinical trials in Glioblastoma (Late-stage disease, Recurrent, Second-line therapy or greater) in USA (IV) (NCT03970447)